Esperite (voorheen Cryo Save) « Terug naar discussie overzicht

quote:

Fulcrumm schreef op 25 november 2016 23:10:

Genoma heeft nu 7 producten, dus denk dat ze wel weten wat ze aan het doen zijn

quote:

DeZwarteRidder schreef op 26 november 2016 09:32:

[...]
Nou, van harte gefeliciteerd met product nr 7...!!

Vraag eens bij je dokter waar je een Genoma test kunt krijgen!

quote:

machmit schreef op 26 november 2016 10:22:

[...]Pavlov

quote:

Fulcrumm schreef op 26 november 2016 10:43:

Daar heeft dzr wel een puntje, om even terug in de tijd te gaan en Bill Clinton zijn quote een beetje aan te passen It's all about marketing, stupid

quote:

Fulcrumm schreef op 26 november 2016 12:05:

Met een test van genoma had het bewijs heel snel geleverd kunnen worden. :-)

quote:

machmit schreef op 26 november 2016 10:22:

[...]Pavlov

quote:

aextracker schreef op 26 november 2016 12:17:

[...]Esperite Genoma raakt Ansoff ; Betreft een businessmodel en verschillende groeistrategieën.
Gezien zijn leeftijd en voortschrijdend inzicht past bij de sigaar van Bill eerder de zgn. "shrimp-shrink"-strategie.
D.w.z.;
- Value of what come out of his mouth shrinks, where ever he has put his money in.
Analogie met ridders uit de middeleeuwen ?
...ook die verloren hun waarde in de loop der tijd t.g.v. voortschrijdend inzicht.
Tracker

quote:

Vitavita schreef op 18 december 2016 20:45:

Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery.
PMID: 25084218 (view PubMed database entry)
DOI: 10.1016/j.jconrel.2014.07.042 (read at publisher's website )

Luisa Pascucci, Valentina Coccè, Arianna Bonomi, Diletta Ami, Piero Ceccarelli, Emilio Ciusani, Lucia Viganò, Alberta Locatelli, Francesca Sisto, Silvia Maria Doglia, Eugenio Parati, Maria Ester Bernardo, Maurizio Muraca, Giulio Alessandri, Gianpietro Bondiolotti, Augusto Pessina,

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. Electronic address: augusto.pessina@unimi.it.

Mesenchymal stromal cells (MSCs) have been proposed for delivering anticancer agents because of their ability to home in on tumor microenvironment. We found that MSCs can acquire strong anti-tumor activity after priming with Paclitaxel (PTX) through their capacity to uptake and then release the drug. Because MSCs secrete a high amount of membrane microvesicles (MVs), we here investigated the role of MVs in the releasing mechanism of PTX. The murine SR4987 line was used as MSC model. The release of PTX from SR4987 in the conditioned medium (CM) was checked by HPLC and the anti-tumor activity of both CM and MVs was tested on the human pancreatic cell line CFPAC-1. MVs were isolated by ultracentrifugation, analyzed by transmission (TEM) and scanning electron microscopy (SEM), and the presence of PTX by the Fourier transformed infrared (FTIR) microspectroscopy. SR4987 loaded with PTX (SR4987PTX) secreted a significant amount of PTX and their CM possessed strong anti-proliferative activity on CFPAC-1. At TEM and SEM, SR4987PTX showed an increased number of "vacuole-like" structures and shed a relevant number of MVs, but did not differ from untreated SR4987. However, SR4987PTX-derived-MVs (SR4987PTX-MVs) demonstrated a strong anti proliferative activity on CFPAC-1. FTIR analysis of SR4987PTX-MVs showed the presence of an absorption spectrum in the corresponding regions of the PTX marker, absent in MVs from SR4987. Our work is the first demonstration that MSCs are able to package and deliver active drugs through their MVs, suggesting the possibility of using MSCs as a factory to develop drugs with a higher cell-target specificity.

J Control Release (Journal of controlled release : official journal of the Controlled Release Society)
[2014, 192:262-270]

quote:

Vitavita schreef op 18 december 2016 21:13:

Eén van de auteurs is Maurizio Muraca.
Er is een koppeling van Muraca met Esperite:
"Professor Muraca has also agreed to join the Scientific Board of The Cell Factory to support EVs products development and clinical translation. Professor Muraca has extensive and long-term experience in immunology, EVs and MSCs research, and the expertise in regulations of advanced therapies use in clinic."

quote:

DeZwarteRidder schreef op 19 december 2016 00:15:

[...]
Dit is een FLUT-bericht zonder enige waarde, deze figuur levert geen cent winst op voor ESP.
De hele Cell Factory is een groot zwart gat waarin het weinige geld verdwijnt dat ESP nog over heeft.
Ik verwacht dat de Cell Factory wordt verkocht of wordt gesloten.